Woodline Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.66M | Sell |
68,937
-63,955
| -48% | -$8.04M | 0.05% | 455 |
|
|
2025
Q1 | $14.7M | Buy |
+132,892
| New | +$14.7M | 0.1% | 286 |
|
|
2024
Q3 | – | Sell |
-14,011
| Closed | -$1.93M | – | 671 |
|
|
2024
Q2 | $1.93M | Sell |
14,011
-109,231
| -89% | -$15M | 0.02% | 415 |
|
|
2024
Q1 | $17M | Buy |
123,242
+21,960
| +22% | +$3.03M | 0.16% | 193 |
|
|
2023
Q4 | $13.3M | Sell |
101,282
-201,803
| -67% | -$26.6M | 0.15% | 198 |
|
|
2023
Q3 | $34.1M | Sell |
303,085
-849,104
| -74% | -$95.5M | 0.4% | 61 |
|
|
2023
Q2 | $109M | Buy |
1,152,189
+753,495
| +189% | +$71.1M | 1.29% | 9 |
|
|
2023
Q1 | $40.4M | Buy |
398,694
+90,283
| +29% | +$9.14M | 0.55% | 34 |
|
|
2022
Q4 | $36.8M | Buy |
+308,411
| New | +$36.8M | 0.49% | 40 |
|
|
2022
Q2 | – | Sell |
-259,635
| Closed | -$24.3M | – | 854 |
|
|
2022
Q1 | $24.3M | Buy |
259,635
+131,992
| +103% | +$12.4M | 0.4% | 71 |
|
|
2021
Q4 | $10.9M | Sell |
127,643
-502,194
| -80% | -$42.8M | 0.16% | 183 |
|
|
2021
Q3 | $60.4M | Buy |
629,837
+244,783
| +64% | +$23.5M | 0.99% | 18 |
|
|
2021
Q2 | $37.5M | Buy |
+385,054
| New | +$37.5M | 0.7% | 34 |
|
|
2020
Q1 | – | Sell |
-71,496
| Closed | -$7.69M | – | 162 |
|
|
2019
Q4 | $7.69M | Buy |
+71,496
| New | +$7.69M | 0.31% | 79 |
|